Jounce Therapeutics Inc (JNCE) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. grew its stake in Jounce Therapeutics Inc (NASDAQ:JNCE) by 35.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,776 shares of the company’s stock after buying an additional 24,572 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Jounce Therapeutics were worth $316,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in JNCE. JPMorgan Chase & Co. boosted its holdings in Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Jounce Therapeutics by 130.6% during the fourth quarter. Acadian Asset Management LLC now owns 139,957 shares of the company’s stock worth $471,000 after purchasing an additional 79,266 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Jounce Therapeutics during the third quarter worth $677,000. Virtu Financial LLC acquired a new position in Jounce Therapeutics during the fourth quarter worth $111,000. Finally, BlackRock Inc. boosted its holdings in Jounce Therapeutics by 4.0% during the third quarter. BlackRock Inc. now owns 1,450,680 shares of the company’s stock worth $9,429,000 after purchasing an additional 55,775 shares during the last quarter. Institutional investors own 72.65% of the company’s stock.

Shares of JNCE opened at $5.87 on Tuesday. Jounce Therapeutics Inc has a 12 month low of $2.66 and a 12 month high of $22.44. The firm has a market cap of $204.74 million, a P/E ratio of -6.98 and a beta of 3.90.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.29. Jounce Therapeutics had a negative net margin of 41.99% and a negative return on equity of 25.69%. The firm had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.86 million. Analysts forecast that Jounce Therapeutics Inc will post -1.2 EPS for the current fiscal year.

Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Tuesday, January 22nd. JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $11.67.

ILLEGAL ACTIVITY WARNING: “Jounce Therapeutics Inc (JNCE) Shares Bought by D. E. Shaw & Co. Inc.” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2019/04/16/jounce-therapeutics-inc-jnce-shares-bought-by-d-e-shaw-co-inc.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Read More: NASDAQ

Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics Inc (NASDAQ:JNCE).

Institutional Ownership by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.